Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Indrayani Biotech Ltd (INDRANIB) is currently trading at 7.38 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Indrayani Biotech Limited, incorporated in 1992, initially focused on horticulture products like cut flowers and hybrid seeds. Its current core business is the manufacture of electric motors and distribution of electrical apparatus. The company has undergone several strategic shifts and restructurings, including significant equity reduction and mergers, transforming from agriculture to industrial manufacturing. Historically, Indrayani faced ecological challenges affecting its agricultural operations, which prompted shifts in its business model towards more sustainable pursuits. Recent ventures into subsidiary incorporation and business amalgamations indicate a strategic intent to diversify and strengthen its operational capabilities and market presence.
Over the past 52 weeks, Indrayani Biotech Ltd has traded between a low of ₹6.71 and a high of ₹23.49. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Indrayani Biotech Ltd has a market capitalization of approximately 35.79. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Indrayani Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -6.05 and operates in the Diversified sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 35.79 Cr, Indrayani Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Indrayani Biotech Ltd operates in the Diversified sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Indrayani Biotech Ltd is -6.05. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
3
Neutral
3
Bullish
8
Bearish
35
Neutral
3
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Financial Results
Board approved unaudited standalone and consolidated financial results for quarter ended Dec 31, 2025; newspaper publication dated Feb 28, 2026 and results with limited review uploaded to company website.
Board Meeting Outcome
Board approved unaudited standalone and consolidated results for quarter ended Dec 31, 2025 (limited review, unmodified), noted CFO Dhinakaran Rajagopal's resignation, appointed Kunisetty Venkateswara Rao as CFO, approved Rs.5 Cr credit and to expedite partly-paid rights issue.
Board Meeting Outcome
Board approved unaudited Q3 FY26 (quarter ended Dec 31, 2025) standalone & consolidated results with a limited review; CFO Dhinakaran Rajagopal resigned and Mr. Kunisetty Venkateswara Rao appointed; Rs.5Cr credit approved; rights issue to be expedited.
Board Meeting Outcome
Board approved unaudited standalone and consolidated results for quarter ended 31-Dec-2025 (limited review with unmodified opinion); CFO resigned and new CFO appointed; Rs.5 Cr credit facility approved; BSE in-principle rights issue noted.
Board Meeting Outcome
Board approved unaudited standalone and consolidated results for quarter ended 31-12-2025 (limited review with unmodified opinion); accepted CFO resignation and appointed Kunisetty Venkateswara Rao; approved Rs 5 Cr credit, to fast‑track partly‑paid rights issue; earlier compliance delays/fine noted and resolved.
Indrayani Biotech Limited, incorporated in 1992, initially focused on horticulture products like cut flowers and hybrid seeds. Its current core business is the manufacture of electric motors and distribution of electrical apparatus.
The company has undergone several strategic shifts and restructurings, including significant equity reduction and mergers, transforming from agriculture to industrial manufacturing.
Historically, Indrayani faced ecological challenges affecting its agricultural operations, which prompted shifts in its business model towards more sustainable pursuits.
Recent ventures into subsidiary incorporation and business amalgamations indicate a strategic intent to diversify and strengthen its operational capabilities and market presence.
Diversified
Diversified - Medium / Small
36 Cr
Low Risk
-6.0
20.7
—
0.5
23.49
7.54
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
62.00 | 39 Cr | 8.16 | 1.32 | 0.00 | 19.04 | 25.10 | 15.16 | |
19.00 | 38 Cr | 5.86 | 0.38 | 0.00 | 5.09 | 5.18 | 4.63 | |
2.22 | 36 Cr | -13.06 | 0.13 | 0.00 | -1.06 | -0.62 | -0.62 | |
7.80 | 36 Cr | -6.05 | 0.47 | 0.00 | -10.20 | -1.46 | -2.67 | |
67.80 | 32 Cr | 49.85 | 0.60 | 0.00 | 1.47 | -1.00 | -0.05 | |
89.20 | 28 Cr | 44.38 | 6.02 | 0.00 | 10.07 | 8.85 | 10.63 | |
13.52 | 27 Cr | 32.98 | 0.00 | 0.00 | -4.62 | 10.24 | 1.91 |
